Transcode Therapeutics Stock Analysis
| RNAZ Stock | USD 9.55 -0.13 -1.34% |
Transcode Therapeutics appears overvalued based on a Real Value estimate of $7.95. This stock analysis focuses on estimating intrinsic value. Intrinsic value estimates what Transcode Therapeutics may be worth independently of its current market price. Coverage is split between fundamental metrics and technical price analysis. Together they provide complementary context for valuation and market behavior.
Transcode Therapeutics' financial leverage reflects the degree to which fixed-income securities are used to finance operations. Debt financing increases interest payments and can shape earnings stability.
Transcode | Build portfolio with Transcode Stock |
Stock Analysis Notes
The company recorded a loss per share of 236.52. Transcode Therapeutics had not issued any dividends in recent years. The company completed a 1:28 stock split on 15th of May 2025. Transcode Therapeutics posted $7.3 million in Total Assets for the reported period.Investor Insights and Alerts
For Transcode Therapeutics, investor alerts are designed to highlight developments that deserve a second look before a position in the stock is increased, reduced, or left unchanged. Used correctly, this section functions as a challenge mechanism: it asks whether the thesis is still intact under the latest information set.
| Transcode Therapeutics is way too risky over 90 days horizon | |
| Transcode Therapeutics appears to be risky and price may revert if volatility continues | |
| Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was -16.75 M with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with -13.34 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Latest headline from thestar.com: Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT |
Market Capitalization
Transcode Therapeutics market capitalization is 8.57 M, placing the company in the nano-cap tier across health care companies. Complementary market value signals include a workforce of about 7 people, about 916.97 K shares outstanding, and operating in the Health Care industry.Technical Drivers
As of the 18th of March 2026, Transcode Therapeutics trades at 9.55 per share. Key technical indicators include Coefficient Of Variation of 1257.57, risk adjusted performance of 0.072, and Semi Deviation of 4.47. The technical model evaluates historical price movement, trading volume, and volatility patterns to quantify trend strength. Current values are evaluated relative to sector peers and historical ranges.Transcode Therapeutics Price Movement Analysis
This analysis covers thirty-eight data points across the selected time horizon. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Transcode Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Transcode Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Insider Trading Activities
Tracking Transcode Therapeutics' insider filings adds context. Executives often respond to business conditions well before market sentiment shifts. The pattern is most useful when compared with earnings releases and guidance changes rather than treated alone.
Outstanding Bonds
Outstanding bonds linked to Transcode Therapeutics can tell investors a great deal about how the company finances itself beyond common equity markets. Current market capitalization is about 8.57 Million. Bond investors and equity investors often care about the same cash flows, but they rank the risks differently.
| TRANSCANADA PIPELINES LTD Corp BondUS893526DF78 | View | |
| TRANSCANADA PIPELINES LTD Corp BondUS893526DJ90 | View | |
| TRANSATLANTIC HLDGS INC Corp BondUS893521AB05 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AB92 | View | |
| US893574AF07 Corp BondUS893574AF07 | View | |
| TRPCN 55 15 SEP 79 Corp BondUS89356BAE83 | View | |
| TRPCN 5875 15 AUG 76 Corp BondUS89356BAB45 | View | |
| TRPCN 56 07 MAR 82 Corp BondUS89356BAG32 | View |
Predictive Daily Indicators
Short-horizon indicators in Transcode Therapeutics turn fast-changing price action into clearer risk and execution cues. Used carefully, they can improve execution without tempting investors to overtrade every small swing.
Forecast Models
A forecast for Transcode Therapeutics starts with historical data. Prices often signal trend and momentum shifts before fundamentals catch up. Forecast models complement fundamental research by showing where price behavior supports or contradicts the thesis.Debt to Cash Allocation
The debt-to-cash mix for Transcode Therapeutics helps explain how management balances flexibility and funding cost through a business cycle.
Transcode Therapeutics currently holds $38.29 K in liabilities. Transcode Therapeutics has a current ratio of 7.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Transcode Therapeutics' use of debt, we should always consider it together with its cash and equity.Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Transcode Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Transcode Therapeutics, which in turn will lower the firm's financial flexibility.Corporate Bonds Issued
Bond maturity for Transcode Therapeutics is a core risk dimension. Longer duration can offer higher yield, but price sensitivity and credit uncertainty also increase.
Stock Analysis Methodology
As a micro-cap equity, Transcode Therapeutics diagnostic profile covers valuation ratios, fundamentals, and technical signals. Transcode Therapeutics trades at P/B of 6.01. Profitability metrics show ROE of -17.63%, ROA of -2.33%. Balance sheet indicators include current ratio of 8.06. Financial distress probability is estimated at 61%. RSI at 51 is in neutral territory. A beta of -0.4135 indicates low sensitivity to broad market moves. Sharpe ratio of 0.0795 reflects the risk-adjusted return profile.
Unless otherwise specified, data for Transcode Therapeutics is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardBe your own money manager
Wealth building around Transcode Therapeutics is more effective when position sizing, diversification, and expected return are reviewed together rather than as separate decisions. A disciplined process can make capital allocation more consistent and less reactive.
Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
| All Next | Launch Module |
Popular Tools for Transcode Stock analysis
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |